Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-G(D2) immunotherapy and isotretinoin

Since 2003, high-risk neuroblastoma (HR-NB) patients at our center received anti-G(D2) antibody 3F8/GM-CSF + isotretinoin – but not myeloablative therapy with autologous stem-cell transplantation (ASCT). Post-ASCT patients referred from elsewhere also received 3F8/GM-CSF + isotretinoin. We therefore...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Kushner, Brian H., Ostrovnaya, Irina, Cheung, Irene Y., Kuk, Deborah, Modak, Shakeel, Kramer, Kim, Roberts, Stephen S., Basu, Ellen M., Yataghene, Karima, Cheung, Nai-Kong V.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2015
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826196/
https://ncbi.nlm.nih.gov/pubmed/26623730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6393
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi